Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,625 across all filing types
Latest filing 2022-08-19 Regulatory Filings
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from Overseas Chinese Town (Asia) Holdings Limited regarding the date of a board meeting to consider and approve the interim results for the six months ended 30 June 2022 and the possible declaration of an interim dividend. It does not contain any actual financial data or detailed report content but merely informs about the upcoming board meeting and the agenda. The document length is only 1546 characters, which is quite short and fits the pattern of an announcement rather than a full interim report. According to the rules, such announcements about meetings to approve reports are classified as Regulatory Filings (RNS) because they do not contain substantive financial data or the report itself.
2022-08-19 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is an announcement from the board of directors of RemeGen Co., Ltd. stating the date of a board meeting to consider and approve the interim results for the six months ended June 30, 2022. The document is short (1500 characters) and does not contain any actual financial data or the interim report itself. It is a notice about the upcoming board meeting and the planned publication of the interim results, not the interim report. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement rather than an Interim Report (IR) or Earnings Release (ER).
2022-08-16 English
CONTINUING CONNECTED TRANSACTION - PROCUREMENT FRAMEWORK AGREEMENT
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a continuing connected transaction under the Listing Rules of the Hong Kong Stock Exchange. It details a Procurement Framework Agreement between the company and a connected person, including terms, annual caps, and compliance with listing rules. The document is a regulatory announcement about a specific transaction and its compliance, not a financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive details about the transaction. The content fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about connected transactions and compliance with listing rules, which does not fit other more specific categories.
2022-08-11 English
DISCLOSEABLE TRANSACTION - PURCHASE OF WEALTH MANAGEMENT PRODUCTS
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the purchase of wealth management products by RemeGen Co., Ltd. It details multiple agreements with Qingdao Bank for purchasing principal-guaranteed bank wealth management products using idle raised proceeds from an A Share Offering. The document discusses the nature of these transactions, their aggregation under listing rules, and the implications under the stock exchange's disclosure requirements. It is a regulatory announcement about a discloseable transaction related to the company's use of funds and investment activities. There is no indication that this is a full financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive transaction details and is not merely stating that a report is available. The document fits best under Capital/Financing Update (CAP) as it concerns the company's financing activities and use of capital raised from share offerings for investment in wealth management products.
2022-08-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2022
Regulatory Filings Classification · 95% confidence The document is a monthly return filed to the Hong Kong Exchanges and Clearing Limited regarding movements in securities for the month ended 31 July 2022. It details movements in authorized/registered share capital, issued shares, and confirms compliance with listing rules. The document is a regulatory submission about share capital and share movements, not a financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive data about share capital and confirmations. The document fits best under Regulatory Filings (RNS) as it is a compliance filing related to securities movements under the Exchange Listing Rules, without being a financial report or announcement of voting results or capital changes per se.
2022-08-04 English
Monthly Return of Equity Issuer on Movement in Securities for the month ended 31 July 2022
Regulatory Filings Classification · 95% confidence The document is a monthly return report detailing movements in securities, specifically authorized and issued shares, for Overseas Chinese Town (Asia) Holdings Limited. It is addressed to the Hong Kong Exchanges and Clearing Limited and includes confirmations related to securities issuance and compliance with listing rules. The document does not contain financial statements or performance data but focuses on share capital movements and confirmations. It is a regulatory submission related to share capital changes and compliance rather than a financial report or announcement of voting results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-08-03 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.